nodes	percent_of_prediction	percent_of_DWPC	metapath
Treprostinil—CYP2C9—Vismodegib—skin cancer	0.134	0.738	CbGbCtD
Treprostinil—CYP2C9—Fluorouracil—skin cancer	0.0476	0.262	CbGbCtD
Treprostinil—PTGIR—Prostanoid ligand receptors—PTGER4—skin cancer	0.0177	0.143	CbGpPWpGaD
Treprostinil—PTGIR—endothelium—skin cancer	0.0167	0.145	CbGeAlD
Treprostinil—PTGIR—blood vessel—skin cancer	0.0154	0.133	CbGeAlD
Treprostinil—PTGIR—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.0118	0.095	CbGpPWpGaD
Treprostinil—P2RY12—epithelium—skin cancer	0.0118	0.102	CbGeAlD
Treprostinil—PTGIR—Small Ligand GPCRs—PTGER4—skin cancer	0.00974	0.0786	CbGpPWpGaD
Treprostinil—PPARD—mammalian vulva—skin cancer	0.00848	0.0733	CbGeAlD
Treprostinil—PTGIR—connective tissue—skin cancer	0.0079	0.0683	CbGeAlD
Treprostinil—PPARD—lymphoid tissue—skin cancer	0.00753	0.0651	CbGeAlD
Treprostinil—PTGIR—epithelium—skin cancer	0.0075	0.0649	CbGeAlD
Treprostinil—PPARD—Adipogenesis—ASIP—skin cancer	0.00749	0.0605	CbGpPWpGaD
Treprostinil—P2RY12—head—skin cancer	0.0073	0.0631	CbGeAlD
Treprostinil—PPARD—female reproductive system—skin cancer	0.00726	0.0628	CbGeAlD
Treprostinil—PTGIR—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.00676	0.0546	CbGpPWpGaD
Treprostinil—PPARD—head—skin cancer	0.00607	0.0524	CbGeAlD
Treprostinil—PTGIR—female reproductive system—skin cancer	0.00557	0.0482	CbGeAlD
Treprostinil—PTGIR—head—skin cancer	0.00466	0.0403	CbGeAlD
Treprostinil—PPARD—Adipogenesis—PLIN2—skin cancer	0.00454	0.0367	CbGpPWpGaD
Treprostinil—PPARD—lymph node—skin cancer	0.00425	0.0367	CbGeAlD
Treprostinil—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—PLIN2—skin cancer	0.0035	0.0283	CbGpPWpGaD
Treprostinil—PTGIR—G alpha (s) signalling events—MC1R—skin cancer	0.0033	0.0267	CbGpPWpGaD
Treprostinil—PTGIR—lymph node—skin cancer	0.00326	0.0282	CbGeAlD
Treprostinil—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.00255	0.0206	CbGpPWpGaD
Treprostinil—PPARD—Ectoderm Differentiation—SHH—skin cancer	0.00237	0.0191	CbGpPWpGaD
Treprostinil—Cardiac failure—Fluorouracil—skin cancer	0.00233	0.00402	CcSEcCtD
Treprostinil—Ill-defined disorder—Imiquimod—skin cancer	0.0023	0.00397	CcSEcCtD
Treprostinil—Dehydration—Temozolomide—skin cancer	0.00229	0.00396	CcSEcCtD
Treprostinil—Nausea—Vismodegib—skin cancer	0.00228	0.00393	CcSEcCtD
Treprostinil—Pneumonia—Bleomycin—skin cancer	0.00226	0.00391	CcSEcCtD
Treprostinil—Angioedema—Imiquimod—skin cancer	0.00226	0.00391	CcSEcCtD
Treprostinil—Pulmonary embolism—Docetaxel—skin cancer	0.00226	0.0039	CcSEcCtD
Treprostinil—Hypokalaemia—Temozolomide—skin cancer	0.00224	0.00387	CcSEcCtD
Treprostinil—Malaise—Imiquimod—skin cancer	0.00223	0.00386	CcSEcCtD
Treprostinil—Syncope—Imiquimod—skin cancer	0.00222	0.00383	CcSEcCtD
Treprostinil—Hypotension—Vemurafenib—skin cancer	0.00221	0.00382	CcSEcCtD
Treprostinil—Palpitations—Imiquimod—skin cancer	0.00219	0.00378	CcSEcCtD
Treprostinil—Loss of consciousness—Imiquimod—skin cancer	0.00218	0.00376	CcSEcCtD
Treprostinil—PTGIR—G alpha (s) signalling events—PTGER4—skin cancer	0.00217	0.0175	CbGpPWpGaD
Treprostinil—Cough—Imiquimod—skin cancer	0.00216	0.00373	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00216	0.00373	CcSEcCtD
Treprostinil—Haematuria—Bleomycin—skin cancer	0.00215	0.00371	CcSEcCtD
Treprostinil—Pneumonia—Dactinomycin—skin cancer	0.00211	0.00365	CcSEcCtD
Treprostinil—Myalgia—Imiquimod—skin cancer	0.00211	0.00364	CcSEcCtD
Treprostinil—Chest pain—Imiquimod—skin cancer	0.00211	0.00364	CcSEcCtD
Treprostinil—Arthralgia—Imiquimod—skin cancer	0.00211	0.00364	CcSEcCtD
Treprostinil—Anxiety—Imiquimod—skin cancer	0.0021	0.00363	CcSEcCtD
Treprostinil—Discomfort—Imiquimod—skin cancer	0.00208	0.0036	CcSEcCtD
Treprostinil—Decreased appetite—Vemurafenib—skin cancer	0.00206	0.00356	CcSEcCtD
Treprostinil—Bronchitis—Temozolomide—skin cancer	0.00205	0.00354	CcSEcCtD
Treprostinil—Fatigue—Vemurafenib—skin cancer	0.00204	0.00353	CcSEcCtD
Treprostinil—Haemoglobin—Bleomycin—skin cancer	0.00203	0.00351	CcSEcCtD
Treprostinil—Oedema—Imiquimod—skin cancer	0.00202	0.00349	CcSEcCtD
Treprostinil—Haemorrhage—Bleomycin—skin cancer	0.00202	0.00349	CcSEcCtD
Treprostinil—Infection—Imiquimod—skin cancer	0.00201	0.00347	CcSEcCtD
Treprostinil—P2RY12—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.002	0.0161	CbGpPWpGaD
Treprostinil—CYP2C9—female reproductive system—skin cancer	0.00199	0.0172	CbGeAlD
Treprostinil—Shock—Imiquimod—skin cancer	0.00199	0.00343	CcSEcCtD
Treprostinil—Tachycardia—Imiquimod—skin cancer	0.00197	0.00341	CcSEcCtD
Treprostinil—Sepsis—Docetaxel—skin cancer	0.00196	0.00338	CcSEcCtD
Treprostinil—Anorexia—Imiquimod—skin cancer	0.00193	0.00333	CcSEcCtD
Treprostinil—Pneumonia—Temozolomide—skin cancer	0.00191	0.0033	CcSEcCtD
Treprostinil—Depression—Temozolomide—skin cancer	0.00189	0.00327	CcSEcCtD
Treprostinil—Thrombophlebitis—Docetaxel—skin cancer	0.00189	0.00327	CcSEcCtD
Treprostinil—Flushing—Bleomycin—skin cancer	0.00187	0.00324	CcSEcCtD
Treprostinil—Body temperature increased—Vemurafenib—skin cancer	0.00187	0.00323	CcSEcCtD
Treprostinil—Pharyngitis—Dactinomycin—skin cancer	0.00187	0.00323	CcSEcCtD
Treprostinil—Urinary tract infection—Temozolomide—skin cancer	0.00184	0.00319	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00184	0.00318	CcSEcCtD
Treprostinil—PTGIR—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00184	0.0148	CbGpPWpGaD
Treprostinil—Insomnia—Imiquimod—skin cancer	0.00183	0.00316	CcSEcCtD
Treprostinil—Paraesthesia—Imiquimod—skin cancer	0.00181	0.00313	CcSEcCtD
Treprostinil—Cardiac failure congestive—Docetaxel—skin cancer	0.00181	0.00312	CcSEcCtD
Treprostinil—P2RY12—GPCR ligand binding—PTCH2—skin cancer	0.0018	0.0145	CbGpPWpGaD
Treprostinil—Dyspnoea—Imiquimod—skin cancer	0.0018	0.00311	CcSEcCtD
Treprostinil—Sinusitis—Temozolomide—skin cancer	0.00178	0.00308	CcSEcCtD
Treprostinil—Dyspepsia—Imiquimod—skin cancer	0.00178	0.00307	CcSEcCtD
Treprostinil—Pneumonia—Fluorouracil—skin cancer	0.00176	0.00304	CcSEcCtD
Treprostinil—Erythema—Bleomycin—skin cancer	0.00176	0.00304	CcSEcCtD
Treprostinil—Decreased appetite—Imiquimod—skin cancer	0.00176	0.00303	CcSEcCtD
Treprostinil—Flushing—Dactinomycin—skin cancer	0.00175	0.00302	CcSEcCtD
Treprostinil—Fatigue—Imiquimod—skin cancer	0.00174	0.00301	CcSEcCtD
Treprostinil—Pain—Imiquimod—skin cancer	0.00173	0.00298	CcSEcCtD
Treprostinil—Haemoglobin—Temozolomide—skin cancer	0.00171	0.00296	CcSEcCtD
Treprostinil—P2RY12—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00171	0.0138	CbGpPWpGaD
Treprostinil—Haemorrhage—Temozolomide—skin cancer	0.0017	0.00294	CcSEcCtD
Treprostinil—Urinary tract infection—Fluorouracil—skin cancer	0.0017	0.00294	CcSEcCtD
Treprostinil—Asthenia—Vemurafenib—skin cancer	0.0017	0.00294	CcSEcCtD
Treprostinil—Pharyngitis—Temozolomide—skin cancer	0.00169	0.00292	CcSEcCtD
Treprostinil—Oedema peripheral—Temozolomide—skin cancer	0.00168	0.0029	CcSEcCtD
Treprostinil—Cardiac failure—Docetaxel—skin cancer	0.00168	0.0029	CcSEcCtD
Treprostinil—Pruritus—Vemurafenib—skin cancer	0.00168	0.0029	CcSEcCtD
Treprostinil—Feeling abnormal—Imiquimod—skin cancer	0.00166	0.00288	CcSEcCtD
Treprostinil—PTGIR—GPCR ligand binding—PTCH2—skin cancer	0.00166	0.0134	CbGpPWpGaD
Treprostinil—Gastrointestinal pain—Imiquimod—skin cancer	0.00165	0.00285	CcSEcCtD
Treprostinil—Epistaxis—Fluorouracil—skin cancer	0.00165	0.00285	CcSEcCtD
Treprostinil—Sinusitis—Fluorouracil—skin cancer	0.00164	0.00283	CcSEcCtD
Treprostinil—Erythema—Dactinomycin—skin cancer	0.00164	0.00283	CcSEcCtD
Treprostinil—Pain in extremity—Docetaxel—skin cancer	0.00164	0.00283	CcSEcCtD
Treprostinil—Ill-defined disorder—Bleomycin—skin cancer	0.00163	0.00282	CcSEcCtD
Treprostinil—Anaemia—Bleomycin—skin cancer	0.00163	0.00281	CcSEcCtD
Treprostinil—Diarrhoea—Vemurafenib—skin cancer	0.00162	0.0028	CcSEcCtD
Treprostinil—Abdominal pain—Imiquimod—skin cancer	0.0016	0.00276	CcSEcCtD
Treprostinil—Body temperature increased—Imiquimod—skin cancer	0.0016	0.00276	CcSEcCtD
Treprostinil—Malaise—Bleomycin—skin cancer	0.00159	0.00274	CcSEcCtD
Treprostinil—Flushing—Temozolomide—skin cancer	0.00158	0.00273	CcSEcCtD
Treprostinil—Haemoglobin—Fluorouracil—skin cancer	0.00158	0.00273	CcSEcCtD
Treprostinil—PTGIR—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00157	0.0127	CbGpPWpGaD
Treprostinil—Rhinitis—Fluorouracil—skin cancer	0.00157	0.00272	CcSEcCtD
Treprostinil—Haemorrhage—Fluorouracil—skin cancer	0.00157	0.00271	CcSEcCtD
Treprostinil—Dizziness—Vemurafenib—skin cancer	0.00157	0.00271	CcSEcCtD
Treprostinil—Pharyngitis—Fluorouracil—skin cancer	0.00156	0.00269	CcSEcCtD
Treprostinil—Cough—Bleomycin—skin cancer	0.00153	0.00265	CcSEcCtD
Treprostinil—Dehydration—Docetaxel—skin cancer	0.00152	0.00263	CcSEcCtD
Treprostinil—Ill-defined disorder—Dactinomycin—skin cancer	0.00152	0.00263	CcSEcCtD
Treprostinil—Anaemia—Dactinomycin—skin cancer	0.00152	0.00262	CcSEcCtD
Treprostinil—Vomiting—Vemurafenib—skin cancer	0.00151	0.0026	CcSEcCtD
Treprostinil—Chest pain—Bleomycin—skin cancer	0.0015	0.00259	CcSEcCtD
Treprostinil—Myalgia—Bleomycin—skin cancer	0.0015	0.00259	CcSEcCtD
Treprostinil—Rash—Vemurafenib—skin cancer	0.00149	0.00258	CcSEcCtD
Treprostinil—Dermatitis—Vemurafenib—skin cancer	0.00149	0.00258	CcSEcCtD
Treprostinil—Headache—Vemurafenib—skin cancer	0.00148	0.00256	CcSEcCtD
Treprostinil—Erythema—Temozolomide—skin cancer	0.00148	0.00256	CcSEcCtD
Treprostinil—Discomfort—Bleomycin—skin cancer	0.00148	0.00256	CcSEcCtD
Treprostinil—Malaise—Dactinomycin—skin cancer	0.00148	0.00255	CcSEcCtD
Treprostinil—Asthenia—Imiquimod—skin cancer	0.00145	0.0025	CcSEcCtD
Treprostinil—Oedema—Bleomycin—skin cancer	0.00143	0.00248	CcSEcCtD
Treprostinil—Back pain—Temozolomide—skin cancer	0.00143	0.00248	CcSEcCtD
Treprostinil—Pruritus—Imiquimod—skin cancer	0.00143	0.00247	CcSEcCtD
Treprostinil—Infection—Bleomycin—skin cancer	0.00143	0.00246	CcSEcCtD
Treprostinil—Nausea—Vemurafenib—skin cancer	0.00141	0.00243	CcSEcCtD
Treprostinil—Thrombocytopenia—Bleomycin—skin cancer	0.0014	0.00243	CcSEcCtD
Treprostinil—Myalgia—Dactinomycin—skin cancer	0.0014	0.00241	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.00139	0.0113	CbGpPWpGaD
Treprostinil—Diarrhoea—Imiquimod—skin cancer	0.00138	0.00239	CcSEcCtD
Treprostinil—Discomfort—Dactinomycin—skin cancer	0.00138	0.00238	CcSEcCtD
Treprostinil—Ill-defined disorder—Temozolomide—skin cancer	0.00138	0.00238	CcSEcCtD
Treprostinil—Anaemia—Temozolomide—skin cancer	0.00137	0.00237	CcSEcCtD
Treprostinil—Anorexia—Bleomycin—skin cancer	0.00137	0.00236	CcSEcCtD
Treprostinil—Erythema—Fluorouracil—skin cancer	0.00137	0.00236	CcSEcCtD
Treprostinil—Angioedema—Temozolomide—skin cancer	0.00136	0.00234	CcSEcCtD
Treprostinil—Hypotension—Bleomycin—skin cancer	0.00134	0.00232	CcSEcCtD
Treprostinil—Oedema—Dactinomycin—skin cancer	0.00134	0.00231	CcSEcCtD
Treprostinil—Malaise—Temozolomide—skin cancer	0.00134	0.00231	CcSEcCtD
Treprostinil—Dizziness—Imiquimod—skin cancer	0.00134	0.00231	CcSEcCtD
Treprostinil—Infection—Dactinomycin—skin cancer	0.00133	0.0023	CcSEcCtD
Treprostinil—P2RY12—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00131	0.0106	CbGpPWpGaD
Treprostinil—Palpitations—Temozolomide—skin cancer	0.00131	0.00226	CcSEcCtD
Treprostinil—Thrombocytopenia—Dactinomycin—skin cancer	0.00131	0.00226	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00131	0.00226	CcSEcCtD
Treprostinil—P2RY12—GPCR ligand binding—MC1R—skin cancer	0.0013	0.0105	CbGpPWpGaD
Treprostinil—Cough—Temozolomide—skin cancer	0.00129	0.00224	CcSEcCtD
Treprostinil—Paraesthesia—Bleomycin—skin cancer	0.00129	0.00223	CcSEcCtD
Treprostinil—Vomiting—Imiquimod—skin cancer	0.00128	0.00222	CcSEcCtD
Treprostinil—Dyspnoea—Bleomycin—skin cancer	0.00128	0.00221	CcSEcCtD
Treprostinil—Anorexia—Dactinomycin—skin cancer	0.00128	0.0022	CcSEcCtD
Treprostinil—Rash—Imiquimod—skin cancer	0.00127	0.0022	CcSEcCtD
Treprostinil—Dermatitis—Imiquimod—skin cancer	0.00127	0.0022	CcSEcCtD
Treprostinil—Pneumonia—Docetaxel—skin cancer	0.00127	0.00219	CcSEcCtD
Treprostinil—Headache—Imiquimod—skin cancer	0.00127	0.00219	CcSEcCtD
Treprostinil—Anaemia—Fluorouracil—skin cancer	0.00126	0.00218	CcSEcCtD
Treprostinil—Arthralgia—Temozolomide—skin cancer	0.00126	0.00218	CcSEcCtD
Treprostinil—Myalgia—Temozolomide—skin cancer	0.00126	0.00218	CcSEcCtD
Treprostinil—Anxiety—Temozolomide—skin cancer	0.00126	0.00217	CcSEcCtD
Treprostinil—Discomfort—Temozolomide—skin cancer	0.00125	0.00216	CcSEcCtD
Treprostinil—Decreased appetite—Bleomycin—skin cancer	0.00125	0.00216	CcSEcCtD
Treprostinil—Pain—Bleomycin—skin cancer	0.00123	0.00212	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00122	0.00211	CcSEcCtD
Treprostinil—Oedema—Temozolomide—skin cancer	0.00121	0.00209	CcSEcCtD
Treprostinil—PTGIR—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00121	0.00976	CbGpPWpGaD
Treprostinil—Infection—Temozolomide—skin cancer	0.0012	0.00208	CcSEcCtD
Treprostinil—Nausea—Imiquimod—skin cancer	0.0012	0.00207	CcSEcCtD
Treprostinil—PTGIR—GPCR ligand binding—MC1R—skin cancer	0.0012	0.00968	CbGpPWpGaD
Treprostinil—Epistaxis—Docetaxel—skin cancer	0.00119	0.00206	CcSEcCtD
Treprostinil—Thrombocytopenia—Temozolomide—skin cancer	0.00119	0.00205	CcSEcCtD
Treprostinil—Feeling abnormal—Bleomycin—skin cancer	0.00118	0.00204	CcSEcCtD
Treprostinil—Myalgia—Fluorouracil—skin cancer	0.00116	0.00201	CcSEcCtD
Treprostinil—Chest pain—Fluorouracil—skin cancer	0.00116	0.00201	CcSEcCtD
Treprostinil—Decreased appetite—Dactinomycin—skin cancer	0.00116	0.00201	CcSEcCtD
Treprostinil—Fatigue—Dactinomycin—skin cancer	0.00115	0.00199	CcSEcCtD
Treprostinil—Anorexia—Temozolomide—skin cancer	0.00115	0.00199	CcSEcCtD
Treprostinil—Discomfort—Fluorouracil—skin cancer	0.00115	0.00199	CcSEcCtD
Treprostinil—Pain—Dactinomycin—skin cancer	0.00114	0.00198	CcSEcCtD
Treprostinil—Haemoglobin—Docetaxel—skin cancer	0.00114	0.00197	CcSEcCtD
Treprostinil—Rhinitis—Docetaxel—skin cancer	0.00114	0.00196	CcSEcCtD
Treprostinil—Body temperature increased—Bleomycin—skin cancer	0.00113	0.00196	CcSEcCtD
Treprostinil—Haemorrhage—Docetaxel—skin cancer	0.00113	0.00196	CcSEcCtD
Treprostinil—P2RY12—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00113	0.00908	CbGpPWpGaD
Treprostinil—Pharyngitis—Docetaxel—skin cancer	0.00112	0.00194	CcSEcCtD
Treprostinil—P2RY12—Signaling Pathways—RHOU—skin cancer	0.00112	0.00903	CbGpPWpGaD
Treprostinil—Oedema peripheral—Docetaxel—skin cancer	0.00112	0.00193	CcSEcCtD
Treprostinil—Oedema—Fluorouracil—skin cancer	0.00112	0.00193	CcSEcCtD
Treprostinil—Infection—Fluorouracil—skin cancer	0.00111	0.00191	CcSEcCtD
Treprostinil—Feeling abnormal—Dactinomycin—skin cancer	0.0011	0.00191	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Temozolomide—skin cancer	0.0011	0.00191	CcSEcCtD
Treprostinil—Insomnia—Temozolomide—skin cancer	0.00109	0.00189	CcSEcCtD
Treprostinil—Gastrointestinal pain—Dactinomycin—skin cancer	0.00109	0.00189	CcSEcCtD
Treprostinil—Thrombocytopenia—Fluorouracil—skin cancer	0.00109	0.00189	CcSEcCtD
Treprostinil—Tachycardia—Fluorouracil—skin cancer	0.00109	0.00188	CcSEcCtD
Treprostinil—Paraesthesia—Temozolomide—skin cancer	0.00109	0.00188	CcSEcCtD
Treprostinil—Dyspnoea—Temozolomide—skin cancer	0.00108	0.00186	CcSEcCtD
Treprostinil—Dyspepsia—Temozolomide—skin cancer	0.00107	0.00184	CcSEcCtD
Treprostinil—Anorexia—Fluorouracil—skin cancer	0.00106	0.00184	CcSEcCtD
Treprostinil—Body temperature increased—Dactinomycin—skin cancer	0.00106	0.00183	CcSEcCtD
Treprostinil—Abdominal pain—Dactinomycin—skin cancer	0.00106	0.00183	CcSEcCtD
Treprostinil—Decreased appetite—Temozolomide—skin cancer	0.00105	0.00182	CcSEcCtD
Treprostinil—Flushing—Docetaxel—skin cancer	0.00105	0.00182	CcSEcCtD
Treprostinil—Fatigue—Temozolomide—skin cancer	0.00104	0.0018	CcSEcCtD
Treprostinil—Hypotension—Fluorouracil—skin cancer	0.00104	0.0018	CcSEcCtD
Treprostinil—PTGIR—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00104	0.00836	CbGpPWpGaD
Treprostinil—Pain—Temozolomide—skin cancer	0.00104	0.00179	CcSEcCtD
Treprostinil—PTGIR—Signaling Pathways—RHOU—skin cancer	0.00103	0.00831	CbGpPWpGaD
Treprostinil—Asthenia—Bleomycin—skin cancer	0.00103	0.00178	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00102	0.00176	CcSEcCtD
Treprostinil—Pruritus—Bleomycin—skin cancer	0.00102	0.00175	CcSEcCtD
Treprostinil—Insomnia—Fluorouracil—skin cancer	0.00101	0.00174	CcSEcCtD
Treprostinil—Paraesthesia—Fluorouracil—skin cancer	0.001	0.00173	CcSEcCtD
Treprostinil—Feeling abnormal—Temozolomide—skin cancer	0.000997	0.00172	CcSEcCtD
Treprostinil—Dyspnoea—Fluorouracil—skin cancer	0.000994	0.00172	CcSEcCtD
Treprostinil—Gastrointestinal pain—Temozolomide—skin cancer	0.00099	0.00171	CcSEcCtD
Treprostinil—Erythema—Docetaxel—skin cancer	0.000986	0.0017	CcSEcCtD
Treprostinil—Dyspepsia—Fluorouracil—skin cancer	0.000982	0.0017	CcSEcCtD
Treprostinil—Decreased appetite—Fluorouracil—skin cancer	0.000969	0.00168	CcSEcCtD
Treprostinil—Asthenia—Dactinomycin—skin cancer	0.00096	0.00166	CcSEcCtD
Treprostinil—Abdominal pain—Temozolomide—skin cancer	0.000957	0.00165	CcSEcCtD
Treprostinil—Body temperature increased—Temozolomide—skin cancer	0.000957	0.00165	CcSEcCtD
Treprostinil—Back pain—Docetaxel—skin cancer	0.000954	0.00165	CcSEcCtD
Treprostinil—Pain—Fluorouracil—skin cancer	0.000954	0.00165	CcSEcCtD
Treprostinil—Muscle spasms—Docetaxel—skin cancer	0.000948	0.00164	CcSEcCtD
Treprostinil—P2RY12—GPCR ligand binding—SHH—skin cancer	0.000928	0.0075	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—PTCH2—skin cancer	0.000925	0.00747	CbGpPWpGaD
Treprostinil—Feeling abnormal—Fluorouracil—skin cancer	0.000919	0.00159	CcSEcCtD
Treprostinil—Diarrhoea—Dactinomycin—skin cancer	0.000916	0.00158	CcSEcCtD
Treprostinil—Vomiting—Bleomycin—skin cancer	0.000912	0.00158	CcSEcCtD
Treprostinil—Anaemia—Docetaxel—skin cancer	0.000912	0.00158	CcSEcCtD
Treprostinil—Rash—Bleomycin—skin cancer	0.000905	0.00156	CcSEcCtD
Treprostinil—Dermatitis—Bleomycin—skin cancer	0.000904	0.00156	CcSEcCtD
Treprostinil—Syncope—Docetaxel—skin cancer	0.000884	0.00153	CcSEcCtD
Treprostinil—Body temperature increased—Fluorouracil—skin cancer	0.000882	0.00152	CcSEcCtD
Treprostinil—P2RY12—GPCR ligand binding—SMO—skin cancer	0.00088	0.00711	CbGpPWpGaD
Treprostinil—P2RY12—GPCR ligand binding—PTCH1—skin cancer	0.00088	0.00711	CbGpPWpGaD
Treprostinil—Palpitations—Docetaxel—skin cancer	0.000872	0.00151	CcSEcCtD
Treprostinil—Asthenia—Temozolomide—skin cancer	0.000868	0.0015	CcSEcCtD
Treprostinil—Loss of consciousness—Docetaxel—skin cancer	0.000867	0.0015	CcSEcCtD
Treprostinil—Cough—Docetaxel—skin cancer	0.000861	0.00149	CcSEcCtD
Treprostinil—P2RY12—GPCR ligand binding—PTGER4—skin cancer	0.000857	0.00692	CbGpPWpGaD
Treprostinil—Pruritus—Temozolomide—skin cancer	0.000856	0.00148	CcSEcCtD
Treprostinil—PTGIR—GPCR ligand binding—SHH—skin cancer	0.000854	0.0069	CbGpPWpGaD
Treprostinil—Nausea—Bleomycin—skin cancer	0.000852	0.00147	CcSEcCtD
Treprostinil—PTGIR—Signaling by GPCR—PTCH2—skin cancer	0.000851	0.00687	CbGpPWpGaD
Treprostinil—Vomiting—Dactinomycin—skin cancer	0.000851	0.00147	CcSEcCtD
Treprostinil—Rash—Dactinomycin—skin cancer	0.000844	0.00146	CcSEcCtD
Treprostinil—Myalgia—Docetaxel—skin cancer	0.00084	0.00145	CcSEcCtD
Treprostinil—Chest pain—Docetaxel—skin cancer	0.00084	0.00145	CcSEcCtD
Treprostinil—Arthralgia—Docetaxel—skin cancer	0.00084	0.00145	CcSEcCtD
Treprostinil—Diarrhoea—Temozolomide—skin cancer	0.000828	0.00143	CcSEcCtD
Treprostinil—PTGIR—GPCR ligand binding—SMO—skin cancer	0.00081	0.00654	CbGpPWpGaD
Treprostinil—PTGIR—GPCR ligand binding—PTCH1—skin cancer	0.00081	0.00654	CbGpPWpGaD
Treprostinil—Oedema—Docetaxel—skin cancer	0.000805	0.00139	CcSEcCtD
Treprostinil—Dizziness—Temozolomide—skin cancer	0.0008	0.00138	CcSEcCtD
Treprostinil—Infection—Docetaxel—skin cancer	0.0008	0.00138	CcSEcCtD
Treprostinil—Nausea—Dactinomycin—skin cancer	0.000795	0.00137	CcSEcCtD
Treprostinil—Shock—Docetaxel—skin cancer	0.000792	0.00137	CcSEcCtD
Treprostinil—Pruritus—Fluorouracil—skin cancer	0.000789	0.00136	CcSEcCtD
Treprostinil—PTGIR—GPCR ligand binding—PTGER4—skin cancer	0.000789	0.00637	CbGpPWpGaD
Treprostinil—Thrombocytopenia—Docetaxel—skin cancer	0.000788	0.00136	CcSEcCtD
Treprostinil—Tachycardia—Docetaxel—skin cancer	0.000786	0.00136	CcSEcCtD
Treprostinil—Vomiting—Temozolomide—skin cancer	0.00077	0.00133	CcSEcCtD
Treprostinil—Anorexia—Docetaxel—skin cancer	0.000767	0.00133	CcSEcCtD
Treprostinil—Rash—Temozolomide—skin cancer	0.000763	0.00132	CcSEcCtD
Treprostinil—Diarrhoea—Fluorouracil—skin cancer	0.000763	0.00132	CcSEcCtD
Treprostinil—Dermatitis—Temozolomide—skin cancer	0.000762	0.00132	CcSEcCtD
Treprostinil—Headache—Temozolomide—skin cancer	0.000758	0.00131	CcSEcCtD
Treprostinil—Hypotension—Docetaxel—skin cancer	0.000752	0.0013	CcSEcCtD
Treprostinil—Dizziness—Fluorouracil—skin cancer	0.000737	0.00127	CcSEcCtD
Treprostinil—P2RY12—GPCR downstream signaling—MC1R—skin cancer	0.000736	0.00594	CbGpPWpGaD
Treprostinil—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000733	0.00127	CcSEcCtD
Treprostinil—Insomnia—Docetaxel—skin cancer	0.000728	0.00126	CcSEcCtD
Treprostinil—Paraesthesia—Docetaxel—skin cancer	0.000723	0.00125	CcSEcCtD
Treprostinil—Nausea—Temozolomide—skin cancer	0.000719	0.00124	CcSEcCtD
Treprostinil—Dyspnoea—Docetaxel—skin cancer	0.000718	0.00124	CcSEcCtD
Treprostinil—Vomiting—Fluorouracil—skin cancer	0.000709	0.00123	CcSEcCtD
Treprostinil—Dyspepsia—Docetaxel—skin cancer	0.000709	0.00122	CcSEcCtD
Treprostinil—Rash—Fluorouracil—skin cancer	0.000703	0.00121	CcSEcCtD
Treprostinil—Dermatitis—Fluorouracil—skin cancer	0.000703	0.00121	CcSEcCtD
Treprostinil—Decreased appetite—Docetaxel—skin cancer	0.0007	0.00121	CcSEcCtD
Treprostinil—Headache—Fluorouracil—skin cancer	0.000699	0.00121	CcSEcCtD
Treprostinil—Fatigue—Docetaxel—skin cancer	0.000694	0.0012	CcSEcCtD
Treprostinil—Pain—Docetaxel—skin cancer	0.000688	0.00119	CcSEcCtD
Treprostinil—PTGIR—GPCR downstream signaling—MC1R—skin cancer	0.000678	0.00547	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—MC1R—skin cancer	0.000669	0.0054	CbGpPWpGaD
Treprostinil—Feeling abnormal—Docetaxel—skin cancer	0.000663	0.00115	CcSEcCtD
Treprostinil—Nausea—Fluorouracil—skin cancer	0.000662	0.00114	CcSEcCtD
Treprostinil—Gastrointestinal pain—Docetaxel—skin cancer	0.000658	0.00114	CcSEcCtD
Treprostinil—Body temperature increased—Docetaxel—skin cancer	0.000636	0.0011	CcSEcCtD
Treprostinil—Abdominal pain—Docetaxel—skin cancer	0.000636	0.0011	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—skin cancer	0.000626	0.00506	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PLIN2—skin cancer	0.000621	0.00501	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—MC1R—skin cancer	0.000615	0.00497	CbGpPWpGaD
Treprostinil—Asthenia—Docetaxel—skin cancer	0.000578	0.000998	CcSEcCtD
Treprostinil—Pruritus—Docetaxel—skin cancer	0.000569	0.000984	CcSEcCtD
Treprostinil—Diarrhoea—Docetaxel—skin cancer	0.000551	0.000952	CcSEcCtD
Treprostinil—P2RY12—Signaling Pathways—PTCH2—skin cancer	0.000546	0.00441	CbGpPWpGaD
Treprostinil—Dizziness—Docetaxel—skin cancer	0.000532	0.00092	CcSEcCtD
Treprostinil—Vomiting—Docetaxel—skin cancer	0.000512	0.000884	CcSEcCtD
Treprostinil—Rash—Docetaxel—skin cancer	0.000508	0.000877	CcSEcCtD
Treprostinil—Dermatitis—Docetaxel—skin cancer	0.000507	0.000876	CcSEcCtD
Treprostinil—Headache—Docetaxel—skin cancer	0.000504	0.000871	CcSEcCtD
Treprostinil—PTGIR—Signaling Pathways—PTCH2—skin cancer	0.000503	0.00406	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CSPG4—skin cancer	0.0005	0.00404	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—PTGER4—skin cancer	0.000484	0.00391	CbGpPWpGaD
Treprostinil—Nausea—Docetaxel—skin cancer	0.000478	0.000826	CcSEcCtD
Treprostinil—P2RY12—Signaling by GPCR—SHH—skin cancer	0.000476	0.00385	CbGpPWpGaD
Treprostinil—PPARD—Adipogenesis—IL6—skin cancer	0.000472	0.00381	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—PTCH1—skin cancer	0.000452	0.00365	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—SMO—skin cancer	0.000452	0.00365	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—PTGER4—skin cancer	0.000446	0.0036	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—PTGER4—skin cancer	0.00044	0.00355	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—SHH—skin cancer	0.000438	0.00354	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—SMO—skin cancer	0.000416	0.00336	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—PTCH1—skin cancer	0.000416	0.00336	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—GLI2—skin cancer	0.000414	0.00334	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—PTGER4—skin cancer	0.000405	0.00327	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MC1R—skin cancer	0.000395	0.00319	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—GLI1—skin cancer	0.000389	0.00314	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—GLI2—skin cancer	0.000381	0.00308	CbGpPWpGaD
Treprostinil—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	0.000374	0.00302	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SUFU—skin cancer	0.000369	0.00298	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MC1R—skin cancer	0.000364	0.00293	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—GLI1—skin cancer	0.000358	0.00289	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ENO2—skin cancer	0.00034	0.00275	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SUFU—skin cancer	0.00034	0.00274	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SHH—skin cancer	0.000281	0.00227	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.00028	0.00226	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—RASA1—skin cancer	0.00028	0.00226	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SMO—skin cancer	0.000267	0.00215	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PTCH1—skin cancer	0.000267	0.00215	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	0.000266	0.00215	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PTGER4—skin cancer	0.00026	0.0021	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SHH—skin cancer	0.000259	0.00209	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—RASA1—skin cancer	0.000257	0.00208	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—ERCC2—skin cancer	0.000254	0.00205	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PTCH1—skin cancer	0.000246	0.00198	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SMO—skin cancer	0.000246	0.00198	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PTGER4—skin cancer	0.000239	0.00193	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FOXO4—skin cancer	0.000229	0.00185	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—NRAS—skin cancer	0.000225	0.00182	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FOXO4—skin cancer	0.000211	0.0017	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—NRAS—skin cancer	0.000207	0.00167	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ERCC2—skin cancer	0.000198	0.00159	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—KRAS—skin cancer	0.000194	0.00156	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—KRAS—skin cancer	0.000178	0.00144	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—TP53—skin cancer	0.000172	0.00139	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—HRAS—skin cancer	0.000165	0.00133	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—TP53—skin cancer	0.000158	0.00128	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TERT—skin cancer	0.000153	0.00124	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—HRAS—skin cancer	0.000151	0.00122	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TERT—skin cancer	0.000141	0.00114	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—NRAS—skin cancer	0.000129	0.00104	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PLIN2—skin cancer	0.000125	0.00101	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—BRAF—skin cancer	0.000121	0.00098	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—NRAS—skin cancer	0.000119	0.000959	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTGS2—skin cancer	0.000118	0.000956	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—BRAF—skin cancer	0.000112	0.000902	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—KRAS—skin cancer	0.000111	0.000897	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—KRAS—skin cancer	0.000102	0.000826	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CSPG4—skin cancer	0.000101	0.000812	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—HRAS—skin cancer	9.45e-05	0.000763	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—IL6—skin cancer	9.04e-05	0.00073	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—HRAS—skin cancer	8.69e-05	0.000702	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—IL6—skin cancer	8.32e-05	0.000672	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NRAS—skin cancer	7.63e-05	0.000616	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NRAS—skin cancer	7.02e-05	0.000567	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ENO2—skin cancer	6.84e-05	0.000552	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KRAS—skin cancer	6.56e-05	0.00053	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KRAS—skin cancer	6.04e-05	0.000488	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TP53—skin cancer	5.83e-05	0.000471	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—HRAS—skin cancer	5.58e-05	0.00045	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TP53—skin cancer	5.37e-05	0.000433	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.35e-05	0.000432	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IL6—skin cancer	5.34e-05	0.000431	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—HRAS—skin cancer	5.14e-05	0.000415	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IL6—skin cancer	4.91e-05	0.000397	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ERCC2—skin cancer	3.97e-05	0.000321	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTGS2—skin cancer	2.38e-05	0.000192	CbGpPWpGaD
